Review of the assessment and management of neonatal abstinence syndrome

Addiction Science and Clinical Practice

Volumn 9, Issue 1, 2014, Pages

  Bagley, Sarah Mary ^a   Wachman, Elisha M ^b   Holland, Erica ^b   Brogly, Susan B ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Neonatal abstinence syndrome assessment; Neonatal abstinence syndrome management; Neonatal abstinence syndrome treatment

Indexed keywords

BUPRENORPHINE; CLONIDINE; METHADONE; NARCOTIC AGENT;

BREAST FEEDING; FEMALE; HUMAN; NEONATAL ABSTINENCE SYNDROME; NEWBORN; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; PROCEDURES;

BREAST FEEDING; BUPRENORPHINE; CLONIDINE; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84964315589     PISSN: 19400632     EISSN: 19400640     Source Type: Journal    
DOI: 10.1186/1940-0640-9-19     Document Type: Review

References (59)

1. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM: Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012, 307 (18): 1934-1940.
2. Hayes MJ, Brown MS: Epidemic of prescription opiate abuse and neonatal abstinence. JAMA. 2012, 307: 1974-1975. 10.1001/jama.2012.4526.
3. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G: Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010, 363 (24): 2320-2331. 10.1056/NEJMoa1005359.
4. Hudak ML, Tan RC, Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics: Neonatal drug withdrawal. Pediatrics. 2012, 129 (2): e540-e560. 10.1542/peds.2011-3212.
5. Jansson LM, Velez M, Harrow C: The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009, 5 (1): 47-55.
6. Wachman EM, Newby PK, Vreeland J, Byun J, Bonganzi A, Bauchner H, Philipp BL: The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med. 2011, 5 (4): 293-299. 10.1097/ADM.0b013e3182266a3a.
7. Kaltenbach K, Holbrook AM, Coyle MG, Heil SH, Salisbury AL, Stine SM, Martin PR, Jones HE: Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction. 2012, 107 (Suppl 1): 45-52.
8. Pritham UA: Breastfeeding promotion for management of neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs. 2013, 42 (5): 517-526. 10.1111/1552-6909.12242.
9. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, Huggins GS, Aranda JV, Davis JM: Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013, 309 (17): 1821-1827. 10.1001/jama.2013.3411.
10. Crocetti MT, Amin DD, Jansson LM: Variability in the evaluation and management of opiate-exposed newborns in Maryland. Clin Pediatr. 2007, 46 (7): 632-635. 10.1177/0009922807300699.
11. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine: ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012, 119 (5): 1070-1076. 10.1097/AOG.0b013e318256496e.
12. World Health Organization: Guidelines for Identification and Management of Substance use and Substance use Disorders in Pregnancy. 2014, Available at http://www.who.int/substance-abuse/publications/pregnancy-guidelines/en/. Last accessed May 13, 2014
13. Substance Abuse and Mental Health Services Administration: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series, No. 43. Available at: http://store.samhsa.gov/product/TIP-43-Medication-Assisted-Treatment-for-Opioid-Addiction-in-Opioid-Treatment-Programs/SMA12-4214. Last accessed May 13, 2014
14. Zelson C, Lee SJ, Casalino M: Neonatal narcotic addiction. Comparative effects of maternal intake of heroin and methadone. New Engl J Med. 1973, 289 (23): 1216-1220. 10.1056/NEJM197312062892303.
15. Kandall SR, Albin S, Gartner LM, Lee KS, Eidelman A, Lowinson J: The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev. 1977, 1 (2): 159-169. 10.1016/0378-3782(77)90017-2.
16. Wilson GS, Desmond MM, Wait RB: Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr. 1981, 98 (5): 716-722. 10.1016/S0022-3476(81)80830-X.
17. Simmat-Durand L, Lejeune C, Gourarier L, Groupe d' Etudes Grossesse et Addictions (GEGA): Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol Feb. 2009, 142 (2): 119-123. 10.1016/j.ejogrb.2008.10.012.
18. Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C: Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol Oct. 2011, 67 (10): 1053-1059. 10.1007/s00228-011-1049-9.
19. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S, Groupe d'Etudes Grossesse et Addictions (GEGA): Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend. 2006, 82: 250-257. 10.1016/j.drugalcdep.2005.10.001.
20. Kakko J, Heilig M, Sarman I: Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008, 96 (1-2): 69-78.
21. Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E: Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res. 2009, 15 (3): 128-134. 10.1159/000210042.
22. Velez M, Jansson LM: The opioid dependent mother and newborn dyad: non-pharmacologic care. J Addict Med. 2008, 2 (3): 113-120. 10.1097/ADM.0b013e31817e6105.
23. Jansson LM, Velez ML: Infants of drug-dependent mothers. Pediatr Rev. 2011, 32 (1): 5-12. 10.1542/pir.32-1-5.
24. Bio LL, Siu A, Poon CY: Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol. 2011, 31 (11): 692-701. 10.1038/jp.2011.116.
25. Kron RE, Finnegan LP, Kaplan SL, Litt M, Phoenix MD: The assessment of behavioral change in infants undergoing narcotic withdrawal: comparative data from clinical and objective methods. Addict Dis. 1975, 2 (1-2): 257-275.
26. Jones HE, Harrow C, O'Grady KE, Crocetti M, Jansson LM, Kaltenbach K: Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison. J Opioid Manag. 2010, 6 (6): 409-413. 10.5055/jom.2010.0038.
27. Lester BM, Tronick EZ, Brazelton TB: The neonatal intensive care unit network neurobehavioral scale procedures. Pediatrics. 2004, 113 (3 Pt 2): 641-667.
28. O'Brien C, Hunt R, Jeffery HE: Measurement of movement is an objective method to assist in assessment of opiate withdrawal in newborns. Arch Dis Child Fetal Neonatal Ed. 2004, 89 (4): F305-F309. 10.1136/adc.2002.025270.
29. Finnegan LP, Connaughton JF, Kron RE, Emich JP: Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975, 2 (1-2): 141-158.
30. Finnegan LP, Kron RE, Connaughton JF, Emich JP: Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm. 1975, 12 (1-2): 19-32.
31. Lipsitz PJ: A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr. 1975, 14 (6): 592-594. 10.1177/000992287501400613.
32. Green M, Suffet F: The neonatal narcotic withdrawal index: a device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse. 1981, 8 (2): 203-213. 10.3109/00952998108999125.
33. Zahorodny W, Rom C, Whitney W, Giddens S, Samuel M, Maichuk G, Marshall R: The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr. 1998, 19 (2): 89-93. 10.1097/00004703-199804000-00005.
34. Jansson LM, Academy of Breastfeeding Medicine Protocol Committee: ABM clinical protocol #21: guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009, 4 (4): 225-228. 10.1089/bfm.2009.9987.
35. Johnston M, Landers S, Noble L, Szucs K, Viehmann L, Section on Breastfeeding: Breastfeeding and the use of human milk. Pediatrics. 2012, 129 (3): e827-e841.
36. Jansson LM, Choo RE, Harrow C, Velez M, Schroeder JR, Lowe R, Huestis MA: Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact. 2007, 23 (2): 184-190. 10.1177/0890334407300336.
37. Gray L, Miller LW, Philipp BL, Blass EM: Breastfeeding is analgesic in healthy newborns. Pediatrics. 2002, 109 (4): 590-593. 10.1542/peds.109.4.590.
38. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J: Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006, 117 (6): e1163-e1169. 10.1542/peds.2005-1561.
39. McQueen KA, Murphy-Oikonen J, Gerlach K, Montelpare W: The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care. 2011, 11 (4): 282-290. 10.1097/ANC.0b013e318225a30c.
40. O'Connor AB, Collett A, Alto WA, O'Brien LM: Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health. 2013, 58 (4): 383-388. 10.1111/jmwh.12009.
41. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E: Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013, 102 (11): 1060-1066.
42. Dryden C, Young D, Hepburn M, Mactier H: Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009, 116 (5): 665-671. 10.1111/j.1471-0528.2008.02073.x.
43. Pritham UA, Paul JA, Hayes MJ: Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs. 2012, 41 (2): 180-190. 10.1111/j.1552-6909.2011.01330.x.
44. Hunseler C, Brückle M, Roth B, Kribs A: Neonatal opiate withdrawal and rooming-in: a retrospective analysis of a single center experience. Klin Padiatr. 2013, 225 (5): 247-251.
45. Abrahams RR, Kelly SA, Payne S, Thiessen PN, Mackintosh J, Janssen PA: Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician. 2007, 53 (10): 1722-1730.
46. D'Apolito K: Comparison of a rocking bed and standard bed for decreasing withdrawal symptoms in drug-exposed infants. MCN Am J Matern Child Nurs. 1999, 24 (3): 138-144. 10.1097/00005721-199905000-00007.
47. Oro AS, Dixon SD: Waterbed care of narcotic-exposed neonates. A useful adjunct to supportive care. Am J Dis Child. 1988, 142 (2): 186-188. 10.1001/archpedi.1988.02150020088036.
48. Maichuk GT, Zahorodny W, Marshall R: Use of positioning to reduce the severity of neonatal narcotic withdrawal syndrome. J Perinatol. 1999, 19 (7): 510-513. 10.1038/sj.jp.7200260.
49. Filippelli AC, White LF, Spellman LW, Broderick M, Highfield ES, Sommers E, Gardiner P: Non-insertive acupuncture and neonatal abstinence syndrome: a case series from an inner city safety net hospital. Glob Adv Health Med. 2012, 1 (4): 48-52. 10.7453/gahmj.2012.1.4.007.
50. Jackson L, Ting A, McKay S, Galea P, Skeoch C: A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2004, 89 (4): F300-F304. 10.1136/adc.2003.033555.
51. Langenfeld S, Birkenfeld L, Herkenrath P, Müller C, Hellmich M, Theisohn M: Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend. 2005, 77 (1): 31-36. 10.1016/j.drugalcdep.2004.07.001.
52. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME: Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008, 122 (3): e601-e607. 10.1542/peds.2008-0571.
53. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME: Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011, 106 (3): 574-580. 10.1111/j.1360-0443.2010.03170.x.
54. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B: Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002, 140 (5): 561-564. 10.1067/mpd.2002.123099.
55. Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, Lewis TR, Yaster M, Gauda EB: Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009, 123 (5): e849-e856. 10.1542/peds.2008-0978.
56. Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R: Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol. 2013, 33 (12): 954-959. 10.1038/jp.2013.95.
57. Sarkar S, Donn SM: Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006, 26 (1): 15-17. 10.1038/sj.jp.7211427.
58. Enhancing the Care of Drug-Exposed Infants: Inter-observer reliability program. Available at http://www.neoadvances.com. Last accessed May 13, 2104
59. Wachman EM, Byun J, Philipp BL: Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med. 2010, 5 (4): 159-164. 10.1089/bfm.2009.0079.